SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Tecartus

GILD·GILEAD SCIENCES, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US (initial approval July 2020, full approval April 2026) and EU (EMA approval 2021).
Why 3/10
Tecartus is already approved and commercialized with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. It is a small and declining revenue contributor within Gilead's diversified portfolio, so impactScore is capped at 3-5 per the rubric for approved drugs with no imminent regulatory decision.
Actionable Insight NEUTRAL

Tecartus has no upcoming binary catalyst; the next major Gilead cell-therapy catalyst is the anito-cel PDUFA date on December 23, 2026, for relapsed/refractory multiple myeloma. Watch for further Tecartus sales erosion in Q4 2026 earnings (late January/early February 2027) and any potential earlier-line trial data that could reverse the decline.

Price Chart

Loading chart...

Executive Summary

Tecartus (brexucabtagene autoleucel) is a CD19-directed CAR T-cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences (NASDAQ: GILD. It was first approved by the FDA in July 2020 for relapsed/refractory mantle cell lymphoma (MCL) and received full FDA full approval in April 2026 based on confirmatory ZUMA-2 Cohort 3 data. It is also approved for relapsed/refractory B-cell ALL. However, sales are declining sharply: Q3 2026 sales fell 28% YoY to $60M, driven by intense competition from other CD19 CAR-T therapies. Tecartus is a small part of Gilead's $31B+ annual revenue and has no upcoming binary catalyst in the next 12 months, making it a neutral watch for investors.

How It Works

Tecartus is a personalized cell therapy (CAR-T) made from a patient's own immune cells. The patient's T cells are collected, genetically modified in a lab to recognize and attack cancer cells that carry a protein called CD19, and then infused back into the patient. The modified T cells act as a living drug, seeking out and destroying CD19-positive cancer cells.

Trial Status

Tecartus received full FDA approval for relapsed/refractory MCL in July 2020 under accelerated approval, converted to full approval in April 2026 based on ZUMA-2 Cohort 3 confirmatory data. It also received FDA approval for relapsed/refractory B-cell ALL in October 2021 based on the ZUMA-2 and ZUMA-3 studies. Long-term follow-up data from ZUMA-2 Cohort 3 was reported at ASH 2024 and in 2026 publications.

The Two-Sided Case

▲ Bull Case4
Tecartus was the first and remains the only CAR-T therapy approved for mantle cell lymphoma, a rare and aggressive blood cancer with high unmet need.
Full FDA approval was granted in April 2026 based on ZUMA-2 Cohort 3 confirmatory data showing a 91% overall response rate, validating the drug's efficacy.
The FDA eliminated the REMS (Risk Evaluation and Mitigation Strategy) requirement for Tecartus in June 2025, reducing post-market regulatory burden and potentially easing access.
Gilead's Kite subsidiary continues to invest in cell therapy manufacturing improvements and earlier-line treatment strategies that could eventually benefit Tecartus.
▼ Bear Case4
Sales are declining sharply: Tecartus revenue fell 28% YoY to $60M in Q3 2026, down from $75M in Q1 2026 and $70M in Q2 2026, driven by in-class competition from other CD19 CAR-T therapies (Breyanzi, Kymriah, Aucatzyl).
The CD19 CAR-T space is the most crowded cell-therapy market, with at least six approved products in the US/EU competing for similar patient populations.
Tecartus is a small and shrinking part of Gilead's overall business (less than 1% of Q3 2026 product sales of $8.3B), limiting its ability to move the stock.
No new indication expansions or pivotal readouts are scheduled for Tecartus in the next 12 months, meaning no binary catalyst to reverse the revenue trajectory.

Upcoming Catalysts

  • No upcoming PDUFA date or pivotal readout scheduled for Tecartus in the next 12 months.
  • Q4 2026 earnings report (expected late January/early February 2027) will show whether Tecartus sales decline continues.
  • Potential earlier-line MCL or ALL trial data presentations at medical conferences (ASH, ASCO) could provide upside if positive.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GILEAD SCIENCES, INC. 8-K GILD ·Originating report

Sources · 14

Hover a chip for the title
1 gilead.com2 fda.gov3 gilead.com4 investors.com5 fda.gov6 gilead.com7 gilead.com8 drugs.com9 fda.gov10 en.wikipedia.org11 fiercepharma.com12 pharmanow.live13 sec.gov14 mantlecellalliance.org